News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
541,531 Results
Type
Article (39546)
Company Profile (73)
Press Release (501912)
Section
Business (151608)
Career Advice (2427)
Deals (27663)
Drug Delivery (97)
Drug Development (72759)
Employer Resources (141)
FDA (13556)
Job Trends (12180)
News (270681)
Policy (26902)
Tag
2024 BioCapital Digital (1)
2024 BioForest Digital (2)
2024 BioForest Standard (1)
2024 BioMidwest Digital (1)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (1)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (6)
2024 Biotech Beach Digital (2)
2024 Biotech Beach Standard (2)
2024 Genetown Standard (2)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (3)
2026 BioCapital Elite (1)
2026 BioMidwest Elite (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (1)
Academia (2526)
Academic (1)
Accelerated approval (2)
Adcomms (26)
Allergies (72)
Alliances (38239)
ALS (83)
Alzheimer's disease (1359)
Antibody-drug conjugate (ADC) (112)
Approvals (13552)
Artificial intelligence (213)
Autoimmune disease (15)
Automation (14)
Bankruptcy (309)
Best Places to Work (9994)
BIOSECURE Act (14)
Biosimilars (85)
Biotechnology (60)
Bladder cancer (58)
Brain cancer (24)
Breast cancer (232)
Cancer (1844)
Cardiovascular disease (156)
Career advice (2036)
Career pathing (31)
CAR-T (132)
Cell therapy (363)
Cervical cancer (14)
Clinical research (59106)
Collaboration (642)
Compensation (237)
Complete response letters (21)
COVID-19 (2453)
CRISPR (35)
C-suite (211)
Cystic fibrosis (82)
Data (1810)
Decentralized trials (2)
Denatured (6)
Depression (44)
Diabetes (229)
Diagnostics (5668)
Digital health (13)
Diversity (4)
Diversity, equity & inclusion (38)
Drug discovery (101)
Drug pricing (90)
Drug shortages (23)
Duchenne muscular dystrophy (79)
Earnings (54351)
Editorial (33)
Employer branding (18)
Employer resources (128)
Events (73945)
Executive appointments (619)
FDA (14549)
Featured Employer (21)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (6)
Funding (603)
Gene editing (90)
Generative AI (18)
Gene therapy (267)
GLP-1 (661)
Government (4090)
Grass and pollen (3)
Guidances (45)
Healthcare (15985)
Huntington's disease (23)
IgA nephropathy (23)
Immunology and inflammation (109)
Indications (24)
Infectious disease (2583)
Inflammatory bowel disease (123)
Inflation Reduction Act (8)
Influenza (45)
Intellectual property (77)
Interviews (522)
IPO (12490)
IRA (41)
Job creations (2575)
Job search strategy (1670)
Kidney cancer (10)
Labor market (16)
Layoffs (402)
Leadership (19)
Legal (5729)
Liver cancer (68)
Lung cancer (285)
Lymphoma (120)
Machine learning (2)
Management (51)
Manufacturing (220)
MASH (66)
Medical device (10539)
Medtech (10543)
Mergers & acquisitions (15582)
Metabolic disorders (601)
Multiple sclerosis (66)
NASH (23)
Neurodegenerative disease (86)
Neuropsychiatric disorders (28)
Neuroscience (1831)
NextGen: Class of 2025 (5525)
Non-profit (3972)
Northern California (1959)
Now hiring (29)
Obesity (316)
Opinion (206)
Ovarian cancer (69)
Pain (75)
Pancreatic cancer (73)
Parkinson's disease (126)
Partnered (15)
Patents (187)
Patient recruitment (89)
Peanut (41)
People (50561)
Pharmaceutical (22)
Pharmacy benefit managers (10)
Phase I (18180)
Phase II (25998)
Phase III (19855)
Pipeline (931)
Podcasts (41)
Policy (101)
Postmarket research (2311)
Preclinical (7381)
Press Release (54)
Prostate cancer (84)
Psychedelics (37)
Radiopharmaceuticals (211)
Rare diseases (333)
Real estate (4086)
Recruiting (56)
Regulatory (18898)
Reports (25)
Research institute (2111)
Resumes & cover letters (356)
Rett syndrome (3)
RNA editing (2)
RSV (35)
Schizophrenia (68)
Series A (107)
Series B (70)
Service/supplier (3)
Sickle cell disease (49)
Southern California (1750)
Special edition (10)
Spinal muscular atrophy (145)
Sponsored (27)
Startups (2724)
State (2)
Stomach cancer (13)
Supply chain (50)
The Weekly (33)
United States (17212)
Vaccines (599)
Venture capitalists (28)
Webinars (11)
Weight loss (219)
Women's health (25)
Worklife (16)
Date
Today (120)
Last 7 days (514)
Last 30 days (2361)
Last 365 days (29129)
2025 (6615)
2024 (30551)
2023 (34094)
2022 (44520)
2021 (47764)
2020 (46280)
2019 (39625)
2018 (30032)
2017 (26941)
2016 (25614)
2015 (29990)
2014 (22447)
2013 (18239)
2012 (19474)
2011 (20496)
2010 (18093)
Location
Africa (718)
Alabama (44)
Alaska (4)
Arizona (137)
Arkansas (11)
Asia (33420)
Australia (6996)
California (4478)
Canada (1655)
China (415)
Colorado (207)
Connecticut (199)
Delaware (109)
Europe (74591)
Florida (713)
Georgia (158)
Idaho (48)
Illinois (423)
India (20)
Indiana (253)
Iowa (5)
Japan (128)
Kansas (85)
Kentucky (18)
Louisiana (6)
Maine (47)
Maryland (724)
Massachusetts (3206)
Michigan (185)
Minnesota (271)
Mississippi (1)
Missouri (68)
Montana (21)
Nebraska (22)
Nevada (49)
New Hampshire (62)
New Jersey (1342)
New Mexico (20)
New York (1322)
North Carolina (740)
North Dakota (5)
Northern California (1959)
Ohio (153)
Oklahoma (5)
Oregon (24)
Pennsylvania (1014)
Puerto Rico (9)
Rhode Island (21)
South America (985)
South Carolina (15)
South Dakota (1)
Southern California (1750)
Tennessee (72)
Texas (688)
Utah (152)
Virginia (115)
Washington D.C. (46)
Washington State (432)
West Virginia (3)
Wisconsin (36)
541,531 Results for "inspyr formerly known as genspera".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Averna Therapeutics, formerly known as Exsilio Therapeutics, Appoints Thomas M. Barnes, Ph.D., as Chief Executive Officer
January 27, 2025
·
3 min read
Breast cancer
AstraZeneca, Daiichi Sankyo’s ADC Wins First Approval Despite Mixed Data
Datroway, formerly known as Dato-DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.
January 21, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Celltrion’s Remdantry™, previously known as Inflectra®, will be available in Canada as of April 1, 2025
March 27, 2025
·
3 min read
Press Releases
Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study
March 3, 2025
·
5 min read
Press Releases
Pentixapharm Receives EUR 6.77 Million for Intangible Assets Formerly Developed by Glycotope
January 7, 2025
·
1 min read
BioMidwest
New Cohort Study Data Shows Baxter’s Expanded Hemodialysis – Known as HDx Therapy – Is Associated With Approximately 25% Lower Mortality Rate for up to Four Years
Baxter International Inc. announced new data showing expanded hemodialysis, known as HDx therapy, enabled by Theranova dialyzer, was associated with an approximately 25% lower all-cause mortality risk for up to four years when compared to high-flux hemodialysis.
May 29, 2024
·
5 min read
Spur Therapeutics (Formerly Freeline) Announces New Name and Brand
Spur Therapeutics, formerly Freeline Therapeutics, today announced a new name and brand to reflect its focus on developing a new generation of gene therapies and advancing the practice of genetic medicine.
June 17, 2024
·
5 min read
Drug Development
AltruBio Raises $225M in Series B to Advance Ulcerative Colitis Candidate
Formerly known as AbGenomics Holding, AltruBio on Tuesday said it will use the funds to push its ulcerative colitis asset into a Phase IIb trial with an anticipated readout in 2026.
May 21, 2024
·
2 min read
·
Tyler Patchen
Drug Development
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis
89bio, Inc. today announced the initiation of its Phase 3 ENLIGHTEN Program evaluating the efficacy and safety of pegozafermin in patients with metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH).
March 12, 2024
·
8 min read
Press Releases
Neurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845/TAK-653)
January 27, 2025
·
6 min read
1 of 54,154
Next
